CES 2026 recap: Morgan Stanley flags ’skyrocketing’ AI demand
This AI-picked telecom is up a whopping +77% in January’s first two sessions
Investors are likely to see this stock as ’next AI power play’: BofA
Futures flat, CES 2026 takes central stage- what’s moving markets
Investing.com --Apogee Therapeutics Inc (NASDAQ:APGE)stock fell 4% in premarket trading Tuesday after the company announced interim results from a Phase 1b trial of its zumilokibart (APG777) treatment in asthma patients.
The clinical-stage biotechnology company reported that zumilokibart demonstrated a favorable safety profile and durable suppression of FeNO, a biomarker of Type 2 inflammation, through 16 weeks for all patients in the trial. For patients with available follow-up data, the suppression continued through 32 weeks, supporting potential for 3- or 6-month dosing.
Despite these positive findings, investors appeared to react cautiously to the data, which came from a small sample size of 19 adult patients with mild-to-moderate asthma.
The company highlighted that the treatment showed a maximum absolute mean FeNO reduction of 45 ppb (60% decrease from baseline) after a single dose. No serious adverse events were reported, with gastroesophageal reflux disease being the only treatment-emergent adverse event observed in more than one patient.
Apogee is advancing zumilokibart beyond dermatology applications, positioning it as what the company calls a "pipeline-in-a-product" with potential across inflammatory and immunology indications. The company is also progressing the treatment in atopic dermatitis with Phase 2 APEX trials, aiming to initiate Phase 3 studies by the end of 2026.
The company reported a strong cash position of $913 million with runway extending into the second half of 2028, supporting advancement toward a potential launch of zumilokibart in 2029.
Apogee expects multiple clinical data readouts in 2026, including results from its Phase 2 APEX trials in atopic dermatitis and its Phase 1b trial of APG279, a combination therapy being tested against Dupixent.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
